美国政府将签署一项扩大对精神病性因药物研究的命令. Trump to sign order expanding federal research into psychedelic ibogaine for PTSD and addiction.

预计特朗普总统将签署一项行政命令,扩大联邦对伊波加因的研究. 这是一种在海外用于治疗PTSD和成的迷幻药物. President Trump is expected to sign an executive order expanding federal research into ibogaine, a psychedelic used overseas for treating PTSD and addiction. 这一举动不会重新分类该药物, 仍然是I表控制的物质, 但旨在为临床试验释放资金以评估其安全性和医疗益处. The move will not reclassify the drug, which remains a Schedule I controlled substance, but aims to unlock funding for clinical trials to assess its safety and medical benefits.